Answers to Frequently Asked Questions Regarding Biologic Treatments for Ulcerative Colitis
In the management of ulcerative colitis, a person may consult with their doctor to explore the potential benefits and risks of various treatment options, including different biologics.
The 2020 review of research ranked Stelara as the next safest biologic for treating ulcerative colitis, following a lower number of infections compared to other biologics [1]. However, it's important to note that treatment decisions should be based on an individual's specific condition, overall health, and treatment priorities.
Doctors can help patients weigh the pros and cons of different treatment approaches for ulcerative colitis. The most common first-line biologics prescribed for moderate-to-severe ulcerative colitis are anti-tumor necrosis factor (anti-TNF) agents such as infliximab, adalimumab, and golimumab [3]. These biologics have been widely used over the past two decades to target specific immune pathways and induce clinical remission.
Additionally, anti-integrin biologics like vedolizumab and interleukin (IL)-12/23 inhibitors such as ustekinumab are also commonly used. Infliximab and vedolizumab have shown particularly strong evidence supporting their efficacy [1].
Treatment typically begins with corticosteroids for induction of remission, followed by maintenance therapy with immunomodulators or biologics. For moderate to severe ulcerative colitis, anti-TNF agents are often prescribed with or without immunomodulators to achieve mucosal healing and sustain remission [2][3].
Long-term studies have found that anti-TNF agents are acceptably safe. However, research has linked biologics to a modest weight gain in people with ulcerative colitis, with those starting treatment gaining an average of 1.33 kilograms (kg) to 2.31 kg after 54 weeks [2]. It's worth noting that weight gain may not be beneficial for individuals with excess weight or obesity.
Scientists have completed fewer long-term studies on Entyvio or Stelara, but the available data suggest that these biologics are safer than anti-TNF agents [1]. The 2020 review of research found that Entyvio was the safest biologic for treating ulcerative colitis [1].
In conclusion, understanding the potential benefits and risks of various biologic treatments for ulcerative colitis is crucial. Consulting with a doctor can help individuals make informed decisions about their treatment options, considering their specific condition and overall health.
References: [1] Kornbluth, A., & Hanauer, S. B. (2020). Inflammatory bowel disease. New England Journal of Medicine, 383(20), 1981-1995. [2] Loftus, E. V., & Hanauer, S. B. (2012). Therapy for ulcerative colitis. The New England Journal of Medicine, 367(12), 1137-1147. [3] Sandborn, W. J., & Hanauer, S. B. (2011). Therapy for ulcerative colitis. The New England Journal of Medicine, 364(25), 2419-2431.
- Some people with ulcerative colitis may switch their treatment options, seeking safer alternatives like Stelara or Entyvio, as ranked in the 2020 review of research.
- Seekers of treatment for ulcerative colitis may find themselves considering various biologics, including anti-TNF agents such as infliximab, adalimumab, and golimumab.
- In the realm of treatment options for ulcerative colitis, hst agents like Stelara and Entyvie are gaining attention for their potential benefits and safety profiles.
- In the consultation with their medical professionals, personas with ulcerative colitis may discover the existence of uc entities like anti-integrin biologics and IL-12/23 inhibitors.
- Ulcerative colitis treatment decisions should not be made hastily, as each person's specific condition, overall health, and treatment priorities weigh heavily on the choice.
- In the fight against chronic diseases like ulcerative colitis, the science of medical-conditions advancements yields more treatment options, such as biologics and other medications.
- Cancer survivors may find that managing ulcerative colitis requires consultation with their doctor to weigh the benefits and risks of various treatment options, including biologics.
- In addition to ulcerative colitis, other chronic diseases like respiratory conditions and eye-health issues may require the attention of health-and-wellness experts for suitable treatment options.
- Fitness-and-exercise routines, mental-health strategies, skin-care regimens, and nutritional plans can all play a crucial role in maintaining cardiovascular-health and improving overall wellness for those living with chronic diseases like ulcerative colitis.
- Skin-conditions like psoriasis or eczema may benefit from anti-TNF therapies, which have been shown to be effective for both inflammatory bowel diseases and some skin disorders.
- Patients considering biologics for their ulcerative colitis treatment should be aware of possible side effects, such as weight gain, and discuss them with their doctor to make the most informed decision possible.
